In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biopharma Quarterly Dealmaking Statistics, Q3 2015

A look at financing, M&A and alliance activity July–September 2015

Executive Summary

Biopharma financing totaled $9.7 billion, almost half from follow-on public offerings; there was big consolidation in the generics and health services industries. AstraZeneca signed a dozen partnerships, many of which focused on oncology.

Advertisement

Related Content

Priority Review Vouchers: Buyers Beware!
The Campaign Against Drug Pricing: Candidates Can Only Hope Voters React As Strongly As Wall Street
In Buzz Of 2015 Pharma Dealmaking, Immuno-Oncology Is Queen Bee
Bristol’s Fibrotic Game Plan: Promedior Acquisition Hinges On Phase II Results
Allergan Moves Into Busy CGRP Class By Buying Merck’s Oral Drugs

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV004308

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel